Adalimumab is prescribed to treat autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis ...

At the beginning of July, seven additional Humira ® (adalimumab) biosimilars, including one interchangeable, joined Amjevita™ (adalimumab-atto) in the US marketplace. Abrilada™ (adalimumab-afzb) is ...

PHILADELPHIA -- Pfizer has made the case for gaining the coveted "interchangeability" status for its adalimumab biosimilar (Abrilada), a study presented here suggested. A pivotal trial involving ...

Dr Oskouei explains the indications for adalimumab and the impact of their extrapolation, as well as differences among adalimumab products. Sonia T. Oskouei, PharmD, BCMAS, DPLA: All biosimilars ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a new autoinjector pen option for Cyltezo, an interchangeable biosimilar to Humira. Cyltezo ...

Among patients with psoriatic arthritis (PsA), treatment with upadacitinib (Rinvoq) led to greater improvements from baseline in Routine Assessment of Patient Index Data 3 (RAPID3) scores compared ...

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; both drugs ...

Please provide your email address to receive an email when new articles are posted on . Humira biosimilar Amjevita can cost $1,558 for commercial plans, a discount of 14% compared with Humira’s 2020 ...

Adalimumab biosimilar AVT02 exhibited comparative efficacy, safety, tolerability, and immunogenicity to the reference drug Humira in patients with moderate-to-severe chronic plaque psoriasis. The ...

PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today announced that ...

Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...

The appraisal committee considered evidence submitted by AbbVie and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...